Preparation method of ledipasvir key intermediate

A system and technology of amide compounds, applied in the field of preparation of key intermediates of ledipasvir, can solve the problems of unstable compounds, difficult removal of disubstituted impurities, affecting the quality of finished drugs, etc.

Active Publication Date: 2016-03-16
WISDOM PHARM CO LTD
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

First of all, 4-bromo-1,2-phenylenediamine is very unstable due to its aromatic ring diamine structure, and is easily oxidized by oxygen in the air during production, packaging, transportation, and feeding, thereby bringing a large amount of impurities into the follow-up reaction, which is why 4-bromo-1,2-phenylenediamine is not easy to commercially purchase in large quanti

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of ledipasvir key intermediate
  • Preparation method of ledipasvir key intermediate
  • Preparation method of ledipasvir key intermediate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] compound (X) The preparation of (X=Br): in a clean four-neck flask, add IV (10.0g, 0.041mol, 1.0eq) and anhydrous CH 2 Cl 2 (50mL), turn on magnetic stirring (nitrogen protection). Add DMAP (20mg, 0.16mmol) and 4-bromo-2-nitroaniline (9.8g, 0.045mol), stir well after adding, add hydroxybenzotriazole (HOBT) (6.1g, 0.045mol) and 1- Ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC . HCl) (8.6 g, 0.045 mol). Stir evenly after adding, cool the reaction system to 5°C, then slowly add triethylamine (TEA) (10.4g, 0.10mol), keep the reaction temperature not higher than 10°C during the dropwise addition. After the dropwise addition, the reaction solution was stirred at room temperature for 20 h. After the reaction was completed, the reaction solution was added with H 2 The reaction was quenched with O (50 mL) and the organic phase was separated. CH for aqueous phase 2 Cl 2 (3×40 mL) for extraction; the organic phases were combined, washed with 1M HCl (50 mL...

Embodiment 2

[0028] compound (X) Preparation of (X=Cl): Add anhydrous CH to a 250mL three-necked flask 2 Cl 2 (90mL), methyl chloroformate (7.5g, 0.079mol) and IV (18.0 g, 0.075 mol, 1.0 eq). After the addition, stir until it dissolves. Slowly cool the system down to 0°C, then slowly add diisopropylethylamine (DIPEA, 10.7g, 0.083mol), and keep the system temperature not exceeding 5°C during the dropwise addition. After the dropwise addition, slowly add 4-chloro-2-nitroaniline (14.2g, 0.083mol) in CH 2 Cl 2 (90mL) solution, keep the temperature of the system not exceeding 10°C during the dropwise addition, and it takes 1h. After the dropwise addition, the system was naturally raised to room temperature and stirred for 3 h. Add H2O (100mL) to the reaction system to quench the reaction, let stand to separate the organic phase, and the aqueous phase with CH 2 Cl 2 (3 x 90 mL) extraction. The organic phases were combined and washed with 1M HCl (100 mL) and then with saturated brine, a...

Embodiment 3

[0030] compound (XI) Preparation of (X=Br): DMF (60mL), 5-bromo-2-nitroaniline (8.4g, 0.039mol), IV (8.5g, 0.035mol, 1.0eq) and N-methylmorpholine (7.8g, 0.078mol). After the reaction system was cooled to 0°C with ice-brine, 2-(7-azobenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU, 14.6g, 0.038mol ). Subsequently, the reaction was naturally raised to room temperature for 3 h. After the reaction system was concentrated under reduced pressure, the residue was added with H 2 O (50mL) and CH 2 Cl 2 (50mL). Separate the organic phase and use CH for the aqueous phase 2 Cl 2 (3 x 50 mL) extraction. The combined organic phases were washed with 1M HCl (30 mL) and then with saturated brine, and the organic phase was dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated to dryness under pressure at 40°C, and the residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate, 5 / 1, then 2 / 1) to obtain ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a preparation method of a ledipasvir key intermediate, and concretely relates to a preparation method of t-butyl (1R,3S,4S)-3-(5-halo-1H-benzimidazolyl-2-yl)-2-azabicyclo[2. 2. 1]heptane-carboxylate. The method has the advantages of low price and massive commercial purchasing of a raw material, and complete avoiding of generation of disubstituted impurities.

Description

technical field [0001] The present invention relates to the key intermediate of ledipasvir (1R,3S,4S)-3-(5-halo-1H-benzimidazol-2-yl)-2-azabicyclo[2.2.1]heptane- A new method for the preparation of tert-butyl 2-carboxylate. Background technique [0002] At present, the global drug market is showing huge business opportunities, which can be seen from the market performance of recently launched new drugs. The vitality of this field has also stimulated the enthusiasm of enterprises for the research and development of new drugs and the process optimization of new drug intermediates. Ledipasvir, formerly known as GS-5885, is an NS5A protease inhibitor developed by Gilead Sciences. After the completion of phase III clinical trials of ledidevir, the tablet of the fixed-dose combination of ledipasvir / sofosbuvir for the treatment of genotype I hepatitis C was included in the United States Pharmacopoeia on February 10, 2014. On October 10, 2014, the combination product ledidevir / so...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D209/52C07D403/04
CPCC07D209/52C07D403/04
Inventor 邱小龙王东辉邓贤明游正伟江中兴黄鑫胡林邹平
Owner WISDOM PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap